股市必读：特一药业（002728）1月9日董秘有最新回复

Core Viewpoint - The company is focusing on expanding its market presence and enhancing the efficacy of its core product, the cough remedy "Zhi Ke Bao Pian," while preparing for potential inclusion in medical insurance programs [2][4]. Product Development and Research - The core product "Zhi Ke Bao Pian" has a history of over a century and is effective for various types of chronic cough, with a clinical effectiveness rate of 93% and a low incidence of side effects [2][4]. - Recent studies have been conducted on the product's efficacy against coughs caused by influenza and lung inflammation, with findings published in reputable journals [2]. - The company aims to strengthen its theoretical support for product promotion and consumer education through ongoing research [2]. Market Strategy - The company is implementing a mixed marketing model combining self-operated teams and promotional service providers to expand market coverage [2]. - Efforts are being made to penetrate key national chain pharmacies, deepen partnerships with O2O and B2C e-commerce platforms, and develop third-party channels such as clinics [2]. Financial Performance - For the first three quarters of 2025, the company reported total revenue of 692 million yuan, a year-on-year increase of 51.86%, and a net profit of 65.22 million yuan, up 985.18% [3]. - Sales of "Zhi Ke Bao Pian" have shown steady recovery, reaching 64% of the sales volume compared to the same period in 2023 [3]. Competitive Advantages - The company possesses significant competitive barriers, including advanced extraction technology, a robust patent system, and a strong brand reputation [4][5]. - The product's clinical validation shows high effectiveness rates for specific cough types, further solidifying its market position [4].